Shift to Everolimus (RAD) Kidney Sparing Study

Safety and Efficacy of Low-dose Cyclosporine in Association With Everolimus to Minimize Renal Dysfunction in Heart Transplant Recipients

The purpose of this study is to verify if the combination of Everolimus with a very low dose of cyclosporine is more effective than the combination of mycophenolate mofetil with low-dose of cyclosporine in reducing the progression of kidney dysfunction in patients with heart transplantation.

Inclusion Criteria:

• Heart Transplant with 1 to 4 years of follow-up
• GFR between 20 and 60 ml/min (calculated with Colkoroft-Gault formula)

Exclusion Criteria:

• Acute rejection in the previous 6 months
• Contraindications to statin therapy
• Ongoing infection
• Ongoing heart failure
• Myocardial infarction or myocardial revascularization after transplant
• Malignancy